PMID- 24887639 OWN - NLM STAT- MEDLINE DCOM- 20150819 LR - 20220321 IS - 1873-7544 (Electronic) IS - 0306-4522 (Linking) VI - 283 DP - 2014 Dec 26 TI - BDNF: no gain without pain? PG - 107-23 LID - S0306-4522(14)00444-8 [pii] LID - 10.1016/j.neuroscience.2014.05.044 [doi] AB - Injury to the adult nervous system promotes the expression and secretion of brain-derived neurotrophic factor (BDNF). Because it promotes neuronal growth, survival and neurogenesis, BDNF may initiate compensatory processes that mitigate the deleterious effects of injury, disease or stress. Despite this, BDNF has been implicated in several injury-induced maladaptive processes including pain, spasticity and convulsive activity. This review will concentrate on the predominant role of BDNF in the initiation and maintenance of chronic and/or neuropathic pain at the spinal, peripheral and central levels. Within the spinal dorsal horn, the pattern of BDNF-induced changes in synaptic transmission across five different, identified neuronal phenotypes bears a striking resemblance to that produced by chronic constriction injury (CCI) of peripheral nerves. The appearance of this "pain footprint" thus reflects multiple sensitizing actions of microglial-derived BDNF. These include changes in the chloride equilibrium potential, decreased excitatory synaptic drive to inhibitory neurons, complex changes in inhibitory (GABA/glycinergic) synaptic transmission, increases in excitatory synaptic drive to excitatory neurons and the appearance of oscillatory activity. BDNF effects are confined to changes in synaptic transmission as there is little change in the passive or active properties of neurons in the superficial dorsal horn. Actions of BDNF in the brain stem and periphery also contribute to the onset and persistence of chronic pain. In spite of its role in compensatory processes that facilitate the recovery of the nervous system from injury, the widespread maladaptive actions of BDNF mean that there is literally "no gain without pain". CI - Copyright (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved. FAU - Smith, Peter A AU - Smith PA AD - Centre for Neuroscience and Department of Pharmacology, 9.75 Medical Sciences Building, University of Alberta, Edmonton, AB T6G 2H7, Canada. Electronic address: peter.a.smith@ualberta.ca. LA - eng GR - MOP 81089/Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20140602 PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 0 (Brain-Derived Neurotrophic Factor) SB - IM MH - Animals MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Humans MH - Models, Biological MH - Pain/*metabolism/*pathology MH - Sensory Receptor Cells/*metabolism OTO - NOTNLM OT - Central sensitization OT - dorsal horn OT - electrophysiology OT - neuropathic pain OT - neurotrophin OT - organotypic culture EDAT- 2014/06/03 06:00 MHDA- 2015/08/20 06:00 CRDT- 2014/06/03 06:00 PHST- 2014/03/13 00:00 [received] PHST- 2014/05/16 00:00 [revised] PHST- 2014/05/21 00:00 [accepted] PHST- 2014/06/03 06:00 [entrez] PHST- 2014/06/03 06:00 [pubmed] PHST- 2015/08/20 06:00 [medline] AID - S0306-4522(14)00444-8 [pii] AID - 10.1016/j.neuroscience.2014.05.044 [doi] PST - ppublish SO - Neuroscience. 2014 Dec 26;283:107-23. doi: 10.1016/j.neuroscience.2014.05.044. Epub 2014 Jun 2.